Taiwan
· Delayed Price · Currency is TWD CHO Pharma Statistics
Total Valuation
CHO Pharma has a market cap or net worth of TWD 10.91 billion. The enterprise value is 8.46 billion.
| Market Cap | 10.91B |
| Enterprise Value | 8.46B |
Important Dates
The last earnings date was Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CHO Pharma has 214.01 million shares outstanding. The number of shares has increased by 12.15% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 214.01M |
| Shares Change (YoY) | +12.15% |
| Shares Change (QoQ) | +7.73% |
| Owned by Insiders (%) | 18.51% |
| Owned by Institutions (%) | 17.06% |
| Float | 143.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.79 |
| P/TBV Ratio | 4.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -33.15 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -33.80 |
Financial Position
The company has a current ratio of 23.43, with a Debt / Equity ratio of 0.01.
| Current Ratio | 23.43 |
| Quick Ratio | 23.03 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.14 |
| Interest Coverage | -594.40 |
Financial Efficiency
Return on equity (ROE) is -12.29% and return on invested capital (ROIC) is -6.91%.
| Return on Equity (ROE) | -12.29% |
| Return on Assets (ROA) | -6.52% |
| Return on Capital (ROIC) | -6.91% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.92% in the last 52 weeks. The beta is 0.07, so CHO Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.07 |
| 52-Week Price Change | -29.92% |
| 50-Day Moving Average | 54.91 |
| 200-Day Moving Average | 58.80 |
| Relative Strength Index (RSI) | 38.68 |
| Average Volume (20 Days) | 214,828 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CHO Pharma had revenue of TWD 1.08 million and -255.25 million in losses. Loss per share was -1.24.
| Revenue | 1.08M |
| Gross Profit | 548,000 |
| Operating Income | -231.82M |
| Pretax Income | -255.25M |
| Net Income | -255.25M |
| EBITDA | -217.21M |
| EBIT | -231.82M |
| Loss Per Share | -1.24 |
Balance Sheet
The company has 2.49 billion in cash and 35.95 million in debt, giving a net cash position of 2.45 billion or 11.47 per share.
| Cash & Cash Equivalents | 2.49B |
| Total Debt | 35.95M |
| Net Cash | 2.45B |
| Net Cash Per Share | 11.47 |
| Equity (Book Value) | 2.88B |
| Book Value Per Share | 13.44 |
| Working Capital | 2.43B |
Cash Flow
In the last 12 months, operating cash flow was -245.44 million and capital expenditures -4.85 million, giving a free cash flow of -250.29 million.
| Operating Cash Flow | -245.44M |
| Capital Expenditures | -4.85M |
| Free Cash Flow | -250.29M |
| FCF Per Share | -1.17 |
Margins
| Gross Margin | 50.65% |
| Operating Margin | -21,424.77% |
| Pretax Margin | -23,590.94% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -23,132.16% |
Dividends & Yields
CHO Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.15% |
| Shareholder Yield | -12.15% |
| Earnings Yield | -2.43% |
| FCF Yield | -2.29% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CHO Pharma has an Altman Z-Score of 61.39.
| Altman Z-Score | 61.39 |
| Piotroski F-Score | n/a |